MedPath
EMA Product

Vizarsin

Product approved by European Medicines Agency (EU)

Basic Information

Vizarsin

Regulatory Information

EMEA/H/C/001076

Authorised

September 21, 2009

June 25, 2009

19

February 23, 2023

Company Information

Slovenia

Šmarješka cesta 6 8501 Novo mesto

KRKA, d.d., Novo mesto

Drug Classification

Generic Medicine

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Vizarsin to be effective, sexual stimulation is required.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Vizarsin. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vizarsin.

© Copyright 2025. All Rights Reserved by MedPath